Real-world use of insertable cardiac monitor remote programming: A multicenter European experience.

ABSTRACT:

Background

Insertable cardiac monitors (ICMs) enable continuous arrhythmia monitoring but generate high transmission volumes, increasing clinical workload. The LUX-Dx ICM (Boston Scientific) allows remote reprogramming of device alert settings, potentially reducing in-office visits.

Objective

This study aimed to evaluate the real-world use of remote reprogramming after its initial commercialization in Europe and its impact on transmission burden.

Methods

Deidentified data were collected from 697 consecutive patients across 23 European centers between 2022 and 2024.

Results

Syncope (48%) was the most frequent indication for ICM implantation. Patients were followed for a median of 9 months (25th-75th percentile 4-13). A total of 401 reprogramming events (0.8 per

SUBMITTER: Fareh S 

PROVIDER: S-EPMC12675123 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature